{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T21:40:03Z","timestamp":1738791603873,"version":"3.37.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,5]]},"DOI":"10.7759\/cureus.78570","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T21:05:01Z","timestamp":1738789501000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparing Glucagon-Like Peptide-1 Receptor Agonists to Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure With Preserved Ejection Fraction: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Moath","family":"Al-Shudifat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bushra","family":"Sumra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyril","family":"Kocherry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hina","family":"Shamim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiran","family":"Jhakri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safeera","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.119.313572","article-title":"Heart failure with preserved ejection fraction in perspective","volume":"124","author":"Pfeffer MA","year":"2019","unstructured":"Pfeffer MA, Shah AM, Borlaug BA. Heart failure with preserved ejection fraction in perspective. Circ Res. 2019, 124:1598-617. 10.1161\/CIRCRESAHA.119.313572","journal-title":"Circ Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan TE","year":"2006","unstructured":"Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006, 355:251-9. 10.1056\/NEJMoa052256","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3112","article-title":"The role of multimorbidity in patients with heart failure across the left ventricular ejection fraction spectrum: data from the Swedish Heart Failure Registry","volume":"26","author":"Tomasoni D","year":"2024","unstructured":"Tomasoni D, Vitale C, Guidetti F, et al.. The role of multimorbidity in patients with heart failure across the left ventricular ejection fraction spectrum: data from the Swedish Heart Failure Registry. Eur J Heart Fail. 2024, 26:854-68. 10.1002\/ejhf.3112","journal-title":"Eur J Heart Fail"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2894","article-title":"Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension","volume":"25","author":"Anker SD","year":"2023","unstructured":"Anker SD, Usman MS, Anker MS, et al.. Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension. Eur J Heart Fail. 2023, 25:936-55. 10.1002\/ejhf.2894","journal-title":"Eur J Heart Fail"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14739","article-title":"Epicardial adipose tissue and pericardial constraint in heart failure with preserved ejection fraction","volume":"11","author":"Crum Y","year":"2024","unstructured":"Crum Y, Hoendermis ES, van Veldhuisen DJ, et al.. Epicardial adipose tissue and pericardial constraint in heart failure with preserved ejection fraction. ESC Heart Fail. 2024, 11:1698-706. 10.1002\/ehf2.14739","journal-title":"ESC Heart Fail"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-024-02396-4","article-title":"Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment","volume":"113","author":"von Haehling S","year":"2024","unstructured":"von Haehling S, Assmus B, Bekfani T, et al.. Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment. Clin Res Cardiol. 2024, 113:1287-305. 10.1007\/s00392-024-02396-4","journal-title":"Clin Res Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2023.04.019","article-title":"Clinical trials of sodium-glucose co-transporter-2 inhibitors for treatment of heart failure","volume":"137","author":"Greene SJ","year":"2024","unstructured":"Greene SJ, Butler J, Kosiborod MN. Clinical trials of sodium-glucose co-transporter-2 inhibitors for treatment of heart failure. Am J Med. 2024, 137:S25-34. 10.1016\/j.amjmed.2023.04.019","journal-title":"Am J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14560","article-title":"Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists","volume":"11","author":"Cimino G","year":"2024","unstructured":"Cimino G, Vaduganathan M, Lombardi CM, et al.. Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists. ESC Heart Fail. 2024, 11:649-61. 10.1002\/ehf2.14560","journal-title":"ESC Heart Fail"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref11","unstructured":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. (2000). https.\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/clc.24283","article-title":"Efficacy and safety of semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"47","author":"Rehman A","year":"2024","unstructured":"Rehman A, Saidullah S, Asad M, et al.. Efficacy and safety of semaglutide in patients with heart failure with preserved ejection fraction and obesity. Clin Cardiol. 2024, 47:e24283. 10.1002\/clc.24283","journal-title":"Clin Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1253\/circrep.CR-19-0018","article-title":"Effects of sodium-glucose cotransporter 2 inhibitor on vascular endothelial and diastolic function in heart failure with preserved ejection fraction - novel prospective cohort study","volume":"1","author":"Sakai T","year":"2019","unstructured":"Sakai T, Miura S. Effects of sodium-glucose cotransporter 2 inhibitor on vascular endothelial and diastolic function in heart failure with preserved ejection fraction - novel prospective cohort study. Circ Rep. 2019, 1:286-95. 10.1253\/circrep.CR-19-0018","journal-title":"Circ Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14347","article-title":"Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction","volume":"10","author":"Clemmer JS","year":"2023","unstructured":"Clemmer JS, Ward TJ, Lirette ST. Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction. ESC Heart Fail. 2023, 10:2010-8. 10.1002\/ehf2.14347","journal-title":"ESC Heart Fail"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-021-00277-0","article-title":"Sodium-glucose cotransporter-2 inhibitor use is associated with a reduced risk of heart failure hospitalization in patients with heart failure with preserved ejection fraction and type 2 diabetes mellitus: a real-world study on a diverse urban Popula","volume":"9","author":"Li W","year":"2022","unstructured":"Li W, Katamreddy A, Kataria R, Myerson ML, Taub CC. Sodium-glucose cotransporter-2 inhibitor use is associated with a reduced risk of heart failure hospitalization in patients with heart failure with preserved ejection fraction and type 2 diabetes mellitus: a real-world study on a diverse urban Popula. Drugs Real World Outcomes. 2022, 9:53-62. 10.1007\/s40801-021-00277-0","journal-title":"Drugs Real World Outcomes"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1253\/circrep.CR-21-0030","article-title":"Effect of the sodium-glucose cotransporter 2 inhibitor canagliflozin for heart failure with preserved ejection fraction in patients with type 2 diabetes","volume":"3","author":"Ueda T","year":"2021","unstructured":"Ueda T, Kasama S, Yamamoto M, et al.. Effect of the sodium-glucose cotransporter 2 inhibitor canagliflozin for heart failure with preserved ejection fraction in patients with type 2 diabetes. Circ Rep. 2021, 3:440-8. 10.1253\/circrep.CR-21-0030","journal-title":"Circ Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon SD","year":"2022","unstructured":"Solomon SD, McMurray JJ, Claggett B, et al.. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022, 387:1089-98. 10.1056\/NEJMoa2206286","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa943","article-title":"Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes","volume":"42","author":"Abraham WT","year":"2021","unstructured":"Abraham WT, Lindenfeld J, Ponikowski P, et al.. Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. Eur Heart J. 2021, 42:700-10. 10.1093\/eurheartj\/ehaa943","journal-title":"Eur Heart J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker SD","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al.. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021, 385:1451-61. 10.1056\/NEJMoa2107038","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/ggi.14363","article-title":"Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes and heart failure with preserved ejection fraction: the EXCEED randomized controlled multicenter study","volume":"22","author":"Akasaka H","year":"2022","unstructured":"Akasaka H, Sugimoto K, Shintani A, et al.. Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes and heart failure with preserved ejection fraction: the EXCEED randomized controlled multicenter study. Geriatr Gerontol Int. 2022, 22:298-304. 10.1111\/ggi.14363","journal-title":"Geriatr Gerontol Int"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.015103","article-title":"Effect of luseogliflozin on heart failure with preserved ejection fraction in patients with diabetes mellitus","volume":"9","author":"Ejiri K","year":"2020","unstructured":"Ejiri K, Miyoshi T, Kihara H, et al.. Effect of luseogliflozin on heart failure with preserved ejection fraction in patients with diabetes mellitus. J Am Heart Assoc. 2020, 9:e015103. 10.1161\/JAHA.119.015103","journal-title":"J Am Heart Assoc"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01536-x","article-title":"The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial","volume":"27","author":"Nassif ME","year":"2021","unstructured":"Nassif ME, Windsor SL, Borlaug BA, et al.. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med. 2021, 27:1954-60. 10.1038\/s41591-021-01536-x","journal-title":"Nat Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod MN","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, et al.. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023, 389:1069-84. 10.1056\/NEJMoa2306963","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod MN","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, et al.. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024, 390:1394-407. 10.1056\/NEJMoa2313917","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh TA","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al.. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021, 42:3599-726. 10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"145","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al.. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022, 145:e895-e1032. 10.1161\/CIR.0000000000001063","journal-title":"Circulation"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2022.25","article-title":"Epicardial fat in heart failure with preserved ejection fraction: bad actor or just lying around?","volume":"9","author":"Oduah MT","year":"2023","unstructured":"Oduah MT, Sundaram V, Reddy YN. Epicardial fat in heart failure with preserved ejection fraction: bad actor or just lying around?. Card Fail Rev. 2023, 9:e06. 10.15420\/cfr.2022.25","journal-title":"Card Fail Rev"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac120","article-title":"Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets","volume":"118","author":"Borlaug BA","year":"2023","unstructured":"Borlaug BA, Jensen MD, Kitzman DW, Lam CS, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res. 2023, 118:3434-50. 10.1093\/cvr\/cvac120","journal-title":"Cardiovasc Res"},{"key":"ref29","article-title":"Prevalence of obesity and severe obesity among adults: United States, 2017-2018","author":"Hales CM","year":"2020","unstructured":"Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017-2018. NCHS Data Brief. 2020, 1-8.","journal-title":"NCHS Data Brief"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.11.081","article-title":"Relationship between physical activity, body mass index, and risk of heart failure","volume":"69","author":"Pandey A","year":"2017","unstructured":"Pandey A, LaMonte M, Klein L, et al.. Relationship between physical activity, body mass index, and risk of heart failure. J Am Coll Cardiol. 2017, 69:1129-42. 10.1016\/j.jacc.2016.11.081","journal-title":"J Am Coll Cardiol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.315913","article-title":"Basic mechanisms of diabetic heart disease","volume":"126","author":"Ritchie RH","year":"2020","unstructured":"Ritchie RH, Abel ED. Basic mechanisms of diabetic heart disease. Circ Res. 2020, 126:1501-25. 10.1161\/CIRCRESAHA.120.315913","journal-title":"Circ Res"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(03)00625-9","article-title":"Diastolic dysfunction is associatedwith altered myocardial metabolism inasymptomatic normotensive patientswith well-controlled type 2 diabetes mellitus","volume":"42","author":"Diamant M","year":"2003","unstructured":"Diamant M, Lamb HJ, Groeneveld Y, et al.. Diastolic dysfunction is associatedwith altered myocardial metabolism inasymptomatic normotensive patientswith well-controlled type 2 diabetes mellitus. J Am Coll Cardiol. 2003, 42:328-35. 10.1016\/S0735-1097(03)00625-9","journal-title":"J Am Coll Cardiol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn153","article-title":"Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme","volume":"29","author":"MacDonald MR","year":"2008","unstructured":"MacDonald MR, Petrie MC, Varyani F, et al.. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008, 29:1377-85. 10.1093\/eurheartj\/ehn153","journal-title":"Eur Heart J"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh TA","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, et al.. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023, 44:3627-39. 10.1093\/eurheartj\/ehad195","journal-title":"Eur Heart J"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.7326\/M24-0019","article-title":"Shifting trends in the indication of glucagon-like peptide-1 receptor agonist prescriptions: a nationwide analysis","volume":"177","author":"Yeo YH","year":"2024","unstructured":"Yeo YH, Rezaie A, Hsieh TY, et al.. Shifting trends in the indication of glucagon-like peptide-1 receptor agonist prescriptions: a nationwide analysis. Ann Intern Med. 2024, 177:1289-91. 10.7326\/M24-0019","journal-title":"Ann Intern Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0857-6","article-title":"Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial","volume":"18","author":"Bizino MB","year":"2019","unstructured":"Bizino MB, Jazet IM, Westenberg JJ, van Eyk HJ, Paiman EH, Smit JW, Lamb HJ. Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial. Cardiovasc Diabetol. 2019, 18:55. 10.1186\/s12933-019-0857-6","journal-title":"Cardiovasc Diabetol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2018.08.007","article-title":"Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic\/obese HFpEF","volume":"6","author":"Kitzman DW","year":"2018","unstructured":"Kitzman DW, Nicklas BJ. Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic\/obese HFpEF. JACC Heart Fail. 2018, 6:1008-10. 10.1016\/j.jchf.2018.08.007","journal-title":"JACC Heart Fail"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications","volume":"398","author":"Brown E","year":"2021","unstructured":"Brown E, Heerspink HJ, Cuthbertson DJ, et al.. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet. 2021, 398:262-76. 10.1016\/S0140-6736(21)00536-5","journal-title":"Lancet"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.01.030","article-title":"Cardiac rehabilitation for patients with heart failure: JACC expert panel","volume":"77","author":"Bozkurt B","year":"2021","unstructured":"Bozkurt B, Fonarow GC, Goldberg LR, et al.. Cardiac rehabilitation for patients with heart failure: JACC expert panel. J Am Coll Cardiol. 2021, 77:1454-69. 10.1016\/j.jacc.2021.01.030","journal-title":"J Am Coll Cardiol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001122","article-title":"Supervised exercise training for chronic heart failure with preserved ejection fraction: a scientific statement from the American Heart Association and American College of Cardiology","volume":"147","author":"Sachdev V","year":"2023","unstructured":"Sachdev V, Sharma K, Keteyian SJ, et al.. Supervised exercise training for chronic heart failure with preserved ejection fraction: a scientific statement from the American Heart Association and American College of Cardiology. Circulation. 2023, 147:e699-715. 10.1161\/CIR.0000000000001122","journal-title":"Circulation"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer M","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, et al.. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025, 392:427-37. 10.1056\/NEJMoa2410027","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/332318-comparing-glucagon-like-peptide-1-receptor-agonists-to-sodium-glucose-cotransporter-2-inhibitors-in-heart-failure-with-preserved-ejection-fraction-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T21:05:04Z","timestamp":1738789504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/332318-comparing-glucagon-like-peptide-1-receptor-agonists-to-sodium-glucose-cotransporter-2-inhibitors-in-heart-failure-with-preserved-ejection-fraction-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":41,"URL":"https:\/\/doi.org\/10.7759\/cureus.78570","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,5]]}}}